Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats

Yaoxue Xuebao

Volumn 39, Issue 12, 2004, Pages 1023-1027

  Dai, Jun Dong ^a   Wang, Xue Qing ^a   Zhang, Tao ^b   Meng, Meng ^a   Zhang, Xuan ^a   Lü, Wan Liang ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b North China Pharmaceutical Company   (China)

Author keywords

Cyclosporine A; Eudragit; Oral bioavailability; pH sensitive nanoparticles; Sandimmune Neoral

Indexed keywords

CYCLOSPORIN A; DRUG CARRIER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SYNTHESIS; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICROEMULSION; NANOPARTICLE; NONHUMAN; PH; RANDOMIZATION; RAT; TECHNIQUE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; HYDROGEN-ION CONCENTRATION; MALE; NANOSTRUCTURES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 14644410396     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lindholm A, Henricsson S, Lind M, et al. Intra-individual variability in the relative availability of eyelosporin after oral dosing [J]. Eur J Clin Pharmacol, 1988,34(5):461-464.
2. Tjai JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa [J]. Br J Clin Pharmacol, 1991,31(3):344-346.
3. Noble S, Markham A. Cyclosporin: a review of pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) [J]. Drugs, 1995,50(5):924-941.
4. Luke DR, Kasiske BL, Matzke GR, et al. Effect of cyclosporin on the isolated perfused rat kidney [J]. Transplantation, 1987,43:795-799.
5. Cavanak T, Sucker H. Cyclosporin. Formulation of dosage forms [J]. Prog Allergy, 1986,38:65-72.
6. Kawashima Y, Niwa T, Handa T, et al. Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method [J]. J Pharm Sci, 1989,78(1):68-72.
7. Malmary MF, Houti I, Labat C, et al. Chronopharmacokinetics of cyclosporine A following a single iv dose in the Wistar rat [J]. Eur J Pharm Sci, 1995,3(1):49-56.
8. Molpeceres J, Guzma' n M, Aberturas MR, et al. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement [J]. J Pharm Sd, 1996,85(2):206-213.
9. Li HS, Zhao JL, Wei SL, et al. Preparation of cyclosporine a loaded polylactic-acid nanoparticles colloids and their orad bioavailabilities on rats [J]. Chin Pharm J, 1999,34(8):532-536.
10. McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable polydl- lactide micro- and nanoparticles in intestinal epithelia [J]. Eur J Pharm Sci, 1998,6(2):153-163.
11. Desai MP, Labhasetwar V, Amidon GL, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size [J]. Pharm Res, 1996,13(12): 1838-1845.
12. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract [J]. Br J Clin Pharmcol, 1992,33(1):39-43.